$PIRS
PIERIS PHARMACEUTICALS, INC.

2016 Q2 Form 10-Q Financial Statement

#000119312516588539 Filed on May 12, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $1.073M $1.247M $217.6K
YoY Change 569.52% 472.85% -84.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.370M $1.970M $2.390M
YoY Change 20.3% -17.57% 191.46%
% of Gross Profit
Research & Development $4.500M $3.659M $1.525M
YoY Change 160.79% 140.02% 24.69%
% of Gross Profit
Depreciation & Amortization -$10.00K $94.52K $78.12K
YoY Change -114.29% 21.0% -18.24%
% of Gross Profit
Operating Expenses $6.868M $5.627M $3.919M
YoY Change 85.9% 43.59% 220.5%
Operating Profit -$5.795M -$4.381M -$3.701M
YoY Change 63.97% 18.35% 451.44%
Interest Expense $0.00 $0.00 $4.170K
YoY Change -100.0% -100.0% -96.18%
% of Operating Profit
Other Income/Expense, Net -$87.80K $219.6K $769.00
YoY Change -2058.1% 28459.17% 31.9%
Pretax Income -$5.883M -$4.161M -$3.705M
YoY Change 66.66% 12.32% 375.01%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.883M -$4.161M -$3.705M
YoY Change 66.66% 12.32% 375.02%
Net Earnings / Revenue -548.37% -333.78% -1702.38%
Basic Earnings Per Share
Diluted Earnings Per Share -$143.9K -$104.4K -$125.7K
COMMON SHARES
Basic Shares Outstanding 39.83M shares 39.83M shares 29.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.40M $31.20M $13.20M
YoY Change 304.0% 136.36%
Cash & Equivalents $40.37M $31.19M $13.17M
Short-Term Investments
Other Short-Term Assets $3.500M $3.600M $1.276M
YoY Change 87.55% 182.19%
Inventory
Prepaid Expenses $507.4K
Receivables $70.26K
Other Receivables $0.00
Total Short-Term Assets $43.88M $34.87M $14.97M
YoY Change 247.11% 132.98%
LONG-TERM ASSETS
Property, Plant & Equipment $2.447M $2.210M $1.786M
YoY Change 35.09% 23.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $127.3K $128.0K $0.00
YoY Change
Total Long-Term Assets $2.574M $2.338M $1.809M
YoY Change 40.22% 29.24%
TOTAL ASSETS
Total Short-Term Assets $43.88M $34.87M $14.97M
Total Long-Term Assets $2.574M $2.338M $1.809M
Total Assets $46.45M $37.21M $16.77M
YoY Change 220.87% 121.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.600M $1.700M $1.500M
YoY Change -23.81% 13.33%
Accrued Expenses $2.325M $2.322M $413.4K
YoY Change 265.88% 461.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $6.419M $6.498M $2.251M
YoY Change 112.39% 188.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $42.06K $39.74K $300.0K
YoY Change -86.34% -86.75%
Total Long-Term Liabilities $42.06K $39.74K $300.0K
YoY Change -86.34% -86.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.419M $6.498M $2.251M
Total Long-Term Liabilities $42.06K $39.74K $300.0K
Total Liabilities $9.163M $10.03M $2.547M
YoY Change 175.14% 293.71%
SHAREHOLDERS EQUITY
Retained Earnings -$89.91M -$84.03M -$69.51M
YoY Change 23.09% 20.88%
Common Stock $128.5M $112.6M $29.43K
YoY Change 436622.56% 382621.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.29M $27.18M $14.23M
YoY Change
Total Liabilities & Shareholders Equity $46.45M $37.21M $16.77M
YoY Change 220.87% 121.79%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$5.883M -$4.161M -$3.705M
YoY Change 66.66% 12.32% 375.02%
Depreciation, Depletion And Amortization -$10.00K $94.52K $78.12K
YoY Change -114.29% 21.0% -18.24%
Cash From Operating Activities -$6.110M $2.030M -$3.720M
YoY Change 106.42% -154.57% 785.71%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K $67.92K $40.65K
YoY Change 66.67% 67.09% 2199.1%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$50.00K -$70.00K -$40.00K
YoY Change 66.67% 75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.28M 0.000 -1.000M
YoY Change -9088.24% -100.0%
NET CHANGE
Cash From Operating Activities -6.110M 2.030M -3.720M
Cash From Investing Activities -50.00K -70.00K -40.00K
Cash From Financing Activities 15.28M 0.000 -1.000M
Net Change In Cash 9.120M 1.960M -4.760M
YoY Change -388.61% -141.18% 1033.33%
FREE CASH FLOW
Cash From Operating Activities -$6.110M $2.030M -$3.720M
Capital Expenditures -$50.00K $67.92K $40.65K
Free Cash Flow -$6.060M $1.962M -$3.761M
YoY Change 106.83% -152.17% 791.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39833023 shares
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13167036
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39833023 shares
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39833023 shares
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
112595106
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
82700
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
449376
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
27176071
CY2016Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39742
CY2016Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1711028
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
733221
CY2016Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2464722
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2322044
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84026743
CY2016Q1 us-gaap Liabilities
Liabilities
10029226
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37205297
CY2016Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3491690
CY2016Q1 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
0
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
39833
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6497794
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1432125
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128020
CY2016Q1 us-gaap Assets
Assets
37205297
CY2016Q1 us-gaap Cash
Cash
31188527
CY2016Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
70259
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2210389
CY2016Q1 us-gaap Assets Current
AssetsCurrent
34866888
CY2016Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3608102
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31188527
CY2016Q1 pirs Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2322044
CY2016Q1 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
873666
CY2016Q1 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
183081
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18474211
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39833023 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39833023 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
112226723
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
194694
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
704597
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
31128293
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23852
CY2015Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1058536
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
194790
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1739380
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79865689
CY2015Q4 us-gaap Liabilities
Liabilities
2821768
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33950061
CY2015Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
0
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
39833
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2797916
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1272574
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126781
CY2015Q4 us-gaap Assets
Assets
33950061
CY2015Q4 us-gaap Cash
Cash
29349124
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2162771
CY2015Q4 us-gaap Assets Current
AssetsCurrent
31660509
CY2015Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2311385
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29349124
CY2015Q4 pirs Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1739380
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29292855 shares
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.86
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7507 pure
CY2015Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
466076
CY2015Q4 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
179223
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3593089
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0166 pure
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40648
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-3704734
CY2015Q1 us-gaap Revenues
Revenues
217621
CY2015Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4170
CY2015Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
1127805
CY2015Q1 us-gaap Interest Paid
InterestPaid
4224
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
727475
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3701333
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
769
CY2015Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
602732
CY2015Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
602732
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4307466
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3704734
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
217335
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5307175
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
3918954
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-40648
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1127805
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1524631
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-545633
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
217335
CY2015Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
440649
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-208047
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2394323
CY2015Q1 us-gaap Depreciation
Depreciation
78117
CY2015Q1 us-gaap Restricted Stock Expense
RestrictedStockExpense
311066
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2026559
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001583648
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7600 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0135 pure
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0161 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.00
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
PIERIS PHARMACEUTICALS, INC.
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Significant estimates are used for, but are not limited to, revenue recognition, deferred tax assets, liabilities and valuation allowances, fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#x2019;s estimates, judgments and assumptions.</p> </div>
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2016Q1 dei Trading Symbol
TradingSymbol
PIRS
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7553 pure
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39833023 shares
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
68870
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
163340
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67919
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-4161054
CY2016Q1 us-gaap Revenues
Revenues
1246644
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1185384
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4380674
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
219620
CY2016Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
163340
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4324394
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4161054
CY2016Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
368383
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5838737
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1839403
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
5627318
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-67919
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3659435
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-119236
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
368383
CY2016Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
597189
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
543037
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1967883
CY2016Q1 us-gaap Depreciation
Depreciation
94521

Files In Submission

Name View Source Status
0001193125-16-588539-index-headers.html Edgar Link pending
0001193125-16-588539-index.html Edgar Link pending
0001193125-16-588539.txt Edgar Link pending
0001193125-16-588539-xbrl.zip Edgar Link pending
d175474d10q.htm Edgar Link pending
d175474dex101.htm Edgar Link pending
d175474dex102.htm Edgar Link pending
d175474dex311.htm Edgar Link pending
d175474dex312.htm Edgar Link pending
d175474dex321.htm Edgar Link pending
d175474dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pirs-20160331.xml Edgar Link completed
pirs-20160331.xsd Edgar Link pending
pirs-20160331_cal.xml Edgar Link unprocessable
pirs-20160331_def.xml Edgar Link unprocessable
pirs-20160331_lab.xml Edgar Link unprocessable
pirs-20160331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending